期刊
CLINICAL CANCER RESEARCH
卷 18, 期 8, 页码 2199-2209出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-11-1669
关键词
-
类别
资金
- NCI [RO1 CA103959]
- NIH [CCSG P30 CA 33572]
- General Clinical Research Center [M01 RR00043]
Purpose: To evaluate IL13R alpha 2 as an immunotherapeutic target for eliminating glioma stem-like cancer initiating cells (GSC) of high-grade gliomas, with particular focus on the potential of genetically engineered IL13R alpha 2-specific primary human CD8(+) CTLs (IL13-zetakine(+) CTL) to target this therapeutically resistant glioma subpopulation. Experimental Design: A panel of low-passage GSC tumor sphere (TS) and serum-differentiated glioma lines were expanded from patient glioblastoma specimens. These glioblastoma lines were evaluated for expression of IL13R alpha 2 and for susceptibility to IL13-zetakine(+) CTL-mediated killing in vitro and in vivo. Results: We observed that although glioma IL13R alpha 2 expression varies between patients, for IL13R alpha 2(pos) cases this antigen was detected on both GSCs and more differentiated tumor cell populations. IL13-zetakine(+) CTL were capable of efficient recognition and killing of both IL13R alpha 2(pos) GSCs and IL13R alpha 2(pos) differentiated cells in vitro, as well as eliminating glioma-initiating activity in an orthotopic mouse tumor model. Furthermore, intracranial administration of IL13-zetakine(+) CTL displayed robust antitumor activity against established IL13R alpha 2(pos) GSC TS-initiated orthotopic tumors in mice. Conclusions: Within IL13R alpha 2 expressing high-grade gliomas, this receptor is expressed by GSCs and differentiated tumor populations, rendering both targetable by IL13-zetakine(+) CTLs. Thus, our results support the potential usefullness of IL13R alpha 2-directed immunotherapeutic approaches for eradicating therapeutically resistant GSC populations. Clin Cancer Res; 18(8); 2199-209. (C) 2012 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据